[1]
Abramova, S.N.; Lazareva, G.A. Pharmacotherapy exacerbations of chronic inflammatory conditions of female genital sphere using to Gepon and Longidaza. Research Result: Pharmacology and Clinical Pharmacology, 2016, 2(4), 55-67.
[2]
Karakitsiou, M.; Varga, Z.; Kriska, M.; Kristova, V. Risk perception of NSAIDs in hospitalized patients in Greece. Bratisl. Lek Listy, 2017, 118(7), 427-430.
[3]
Lee, T.A.; Bartle, B.; Weiss, K.B. Impact of NSAIDs on mortality and the effect of preexisting coronary artery disease in US veterans. Am. J. Med., 2007, 120(1), 98.
[4]
Hawkey, C.J. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology, 2000, 119(2), 521-535.
[5]
El-Setouhy, D.A.; Gamiel, A.A.; Badawi, A.A.; Osman, A.S.; Labib, D.A. Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: Accelerated stability study and anti-inflammatory and ulcerogenic effects. Pharm. Dev. Technol., 2017, 22(2), 256-265.
[6]
Halici, Z.; Polat, B.; Cadirci, E.; Topcu, A.; Karakus, E.; Kose, D.; Albayrak, A.; Bayir, Y. Inhibiting renin angiotensin system in rate limiting step by aliskiren as a new approach for preventing indomethacin induced gastric ulcers. Chem. Biol. Interact., 2016, 258(258), 266-275.
[7]
Bjorkman, D.J. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: Risk factors and frequency of complications. Am. J. Med., 1999, 107(6A), 3S-8S.
[8]
Solomon, D.H.; Husni, M.E.; Libby, P.A.; Yeomans, N.D.; Lincoff, A.M.; Lüscher, T.F.; Menon, V.; Brennan, D.M.; Wisniewski, L.M.; Nissen, S.E.; Borer, J.S. The risk of major NSAID toxicity with Celecoxib, Ibuprofen or Naproxen: A secondary analysis of the PRECISION randomized controlled clinical trial. Am. J. Med., 2017, 130(12), 1415-1422.
[9]
Bahmani, M.; Sarrafchi, A.; Shirzad, H.; Asgari, S.; Rafieian-Kopaei, M. Cardiovascular toxicity of cyclooxygenase inhibitors and promising natural substitutes. Curr. Pharm. Des., 2017, 23(6), 952-960.
[10]
Strom, B.L.; Carson, J.L.; Schinnar, R.; Snyder, E.S.; Shaw, M.; Lundin, F.E., Jr Nonsteroidal anti-inflammatory drugs and neutropenia. Arch. Intern. Med., 1993, 153(18), 2119-2124.
[11]
Oude Munnik, T.H.; Annink-Smoors, M.; Hom, H.W.; Sportel, E.T. [Agranulocytosis and septic shock after metamizole use]. Ned. Tijdschr. Geneeskd., 2016, 160, A9464.
[12]
Patton, W.; Duffull, S. Idiosyncratic drug-induced hematological abnormalities. Drug Saf., 1994, 11(6), 445-462.
[13]
Pedrazas López, D.; de Pablo Márquez, B.; García Font, D. Methamizole-induced agranulocytosis. Medicina Clínica Facultad de Medicina de Barcelona, 2016, 146(7)e41
[14]
Hirano, A.; Kimura, G.; Okada, C.; Soda, R.; Takahashi, K. Drug-induced asthma. Nihon Rinsho, 2007, 65(8)(Suppl. 8), 410-414.
[15]
Bort, R.; Ponsoda, X.; Jover, R.; Gómez-Lechón, M.J.; Castell, J.V. Diclofenac toxicity to hepatocytes: A role for drug metabolism in cell toxicity. J. Pharmacol. Exp. Ther., 1999, 288(1), 65-72.
[16]
Teoh, N.C.; Farrell, G.C. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin. Liver Dis., 2003, 7(2), 401-413.
[17]
Pathan, E.; Gaitonde, S.; Rajadhyaksha, S.; Sule, A.; Mittal, G.; Joshi, V.R. A longitudinal study of serum creatinine levels in patients of rheumatoid arthritis on long term NSAID therapy. J. Assoc. Physicians India, 2003, 51, 1045-1049.
[18]
Van Staa, T.P.; Travis, S.; Leufkens, H.G.; Logan, R.F. 5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study. Gastroenterology, 2004, 126(7), 1733-1739.
[19]
Zhang, X.; Donnan, P.T.; Bell, S.; Guthrie, B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: Systematic review and meta-analysis. BMC Nephrol., 2017, 18(1), 256.
[20]
Kravchenko, D.V.; Beskhmelnitsyna, E.A.; Korokin, M.V.; Avtina, T.V.; Sernov, L.N.; Tishin, A.N.; Kostina, D.A. Molecular screening of prospective candidates for TRPA1 ion channel selective antagonists. Research Result: Pharmacology and Clinical Pharmacology, 2016, 1(2), 63-66.
[21]
Watanabe, H. Takayoshi Ohba1; Kazuhiro Satoh; Masaaki Sano; Shioya, T.; Ito, H. TRPV1 and TRPA1 in pulmonary vagal afferents and their relations to airway sensitivity. Antiinflamm. Antiallergy Agents Med. Chem., 2011, 10, 18-30.
[22]
Hodge, H.; Sterner, K. Clinical Toxicology of Commercial Products: Acute Poisoning, 4th ed; Williams and Wilkins, 1975, p. 427.
[23]
Beskhmelnitsyna, E.A.; Kravchenko, D.V.; Sernov, L.N.; Dolzhikova, I.N.; Avtina, T.V.; Kulikov, A.L.; Rozhnova, D.V.; Yakushev, V.I.; Martynov, M.A. Search and evaluation of pharmacodynamic and pharmacokinetic parameters of selective blocker of TRPA1 ion channels from the group of substituted pyrazinopyrimidinones. Research Result: Pharmacology and Clinical Pharmacology, 2018, 4(3), 49-62.
[24]
Yu, S.; Ouyang, A. TRPA1 in bradykinin-induced mechanical hypersensitivity of vagal C fibers in guinea pig esophagus. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296(2), G255-G265.
[25]
Nakao, S.; Mabuchi, M.; Wang, S.; Kogure, Y.; Shimizu, T.; Noguchi, K.; Tanaka, A.; Dai, Y. Synthesis of resveratrol derivatives as new analgesic drugs through desensitization of the TRPA1 receptor. Bioorg. Med. Chem. Lett., 2017, 27(14), 3167-3172.
[26]
Pryde, D.C.; Marron, B.E.; West, C.W.; Reister, S.; Amato, G.; Yoger, K.; Antonio, B.; Padilla, K.; Cox, P.J.; Turner, J.; Warmus, J.S.; Swain, N.A.; Omoto, K.; Mahoney, J.H.; Gerlach, A.C. Discovery of a series of indazole TRPA1 antagonists. ACS Med. Chem. Lett., 2017, 8(6), 666-671.
[27]
McNamara, C.R.; Mandel-Brehm, J.; Bautista, D.M.; Siemens, J.; Deranian, K.L.; Zhao, M.; Hayward, N.J.; Chong, J.A.; Julius, D.; Moran, M.M.; Fanger, C.M. TRPA1 mediates formalin-induced pain. Proc. Natl. Acad. Sci. USA, 2007, 104(33), 13525-13530.
[28]
Wei, H.; Hämäläinen, M.M.; Saarnilehto, M.; Koivisto, A.; Pertovaara, A. Attenuation of mechanical hypersensitivity by an antagonist of the TRPA1 ion channel in diabetic animals. Anesthesiology, 2009, 111(1), 147-154.
[29]
Green, D.; Ruparel, S.; Gao, X.; Ruparel, N.; Patil, M.; Akopian, A.; Hargreaves, K. Central activation of TRPV1 and TRPA1 by novel endogenous agonists contributes to mechanical allodynia and thermal hyperalgesia after burn injury. Mol. Pain, 2016, 12(12)1744806916661725
[30]
Eid, S.R.; Crown, E.D.; Moore, E.L.; Liang, H.A.; Choong, K.C.; Dima, S.; Henze, D.A.; Kane, S.A.; Urban, M.O. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol. Pain, 2008, 4, 48.
[31]
Taylor-Clark, T.E.; Undem, B.J.; Macglashan, D.W., Jr; Ghatta, S.; Carr, M.J.; McAlexander, M.A. Prostaglandin-induced activation of nociceptive neurons via direct interaction with transient receptor potential A1 (TRPA1). Mol. Pharmacol., 2008, 73(2), 274-281.
[32]
Yang, H.; Li, S. Transient receptor potential ankyrin 1 (TRPA1) channel and neurogenic inflammation in pathogenesis of asthma. Med. Sci. Monit., 2016, 22, 2917-2923.
[33]
Radresa, O.; Dahllöf, H.; Nyman, E.; Nolting, A.; Albert, J.S.; Raboisson, P. Roles of TRPA1 in pain pathophysiology and implications for the development of a new class of analgesic drugs. Open Pain J., 2013, 6, 137-153.
[34]
Skerratt, S. Recent progress in the discovery and development of TRPA1 modulators. Prog. Med. Chem., 2017, 56, 81-115.
[35]
Moilanen, L.J.; Hämäläinen, M.; Lehtimäki, L.; Nieminen, R.M.; Moilanen, E. Urate crystal induced inflammation and joint pain are reduced in transient receptor potential ankyrin 1 deficient mice-potential role for transient receptor potential ankyrin 1 in gout. PLoS One, 2015, 10(2)e0117770
[36]
de David Antoniazzi, C.T.; De Prá, S.D.; Ferro, P.R.; Silva, M.A.; Adamante, G.; de Almeida, A.S.; Camponogara, C.; da Silva, C.R.; de Bem Silveira, G.; Silveira, P.C.L.; Oliveira, S.M.; Rigo, F.K.; De Logu, F.; Nassini, R.; Trevisan, G. Topical treatment with a transient receptor potential ankyrin 1 (TRPA1) antagonist reduced nociception and inflammation in a thermal lesion model in rats. Eur. J. Pharm. Sci., 2018, 125, 28-38.
[37]
Mukhopadhyay, I.; Kulkarni, A.; Aranake, S.; Karnik, P.; Shetty, M.; Thorat, S.; Ghosh, I.; Wale, D.; Bhosale, V.; Khairatkar-Joshi, N. Transient receptor potential ankyrin 1 receptor activation in vitro and in vivo by pro-tussive agents: GRC 17536 as a promising anti-tussive therapeutic. PLoS One, 2014, 9(5)e97005
[38]
Skerratt, S.E.; West, C.W. Ion channel therapeutics for pain. Channels (Austin), 2015, 9(6), 344-351.
[39]
Koivisto, A.; Jalava, N.; Bratty, R.; Pertovaara, A. TRPA1 antagonists for pain relief. Pharmaceuticals (Basel), 2018, 11(4), 117.
92
6
1
1